IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.116
EU - Europa 2.848
AS - Asia 1.514
AF - Africa 63
SA - Sud America 18
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.565
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.075
CN - Cina 859
IT - Italia 712
IE - Irlanda 582
SE - Svezia 524
SG - Singapore 467
FI - Finlandia 395
DE - Germania 210
UA - Ucraina 148
TR - Turchia 85
CI - Costa d'Avorio 61
FR - Francia 60
GB - Regno Unito 59
IN - India 49
BE - Belgio 46
AT - Austria 41
CA - Canada 41
NL - Olanda 20
CZ - Repubblica Ceca 16
HK - Hong Kong 13
BR - Brasile 12
JP - Giappone 12
IR - Iran 10
VN - Vietnam 8
HU - Ungheria 7
AR - Argentina 4
LT - Lituania 4
RO - Romania 4
CH - Svizzera 3
ES - Italia 3
LU - Lussemburgo 3
NZ - Nuova Zelanda 3
PL - Polonia 3
AL - Albania 2
DK - Danimarca 2
EU - Europa 2
PK - Pakistan 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
CY - Cipro 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
ZA - Sudafrica 1
Totale 7.565
Salva come PNG Salva come JPEG
Città #
Dublin 580
Chandler 515
Singapore 366
Ann Arbor 314
Santa Clara 312
Parma 224
Jacksonville 185
Beijing 172
Boardman 171
Dearborn 167
Ashburn 162
Nanjing 116
Shanghai 111
Princeton 89
Izmir 82
Chicago 79
Abidjan 61
Milan 60
New York 59
Bremen 57
Wilmington 57
San Mateo 55
Nanchang 50
Kunming 48
Helsinki 46
Shenyang 46
Vienna 40
Marseille 34
Hefei 31
Los Angeles 31
Brussels 29
Des Moines 29
Hebei 29
Jinan 28
Tianjin 28
Toronto 24
Seattle 22
Grafing 21
Modena 21
Woodbridge 21
Pune 20
Changsha 19
Norwalk 19
Redmond 19
Guangzhou 18
Rome 18
Jiaxing 17
Fremont 15
London 14
Munich 14
Leawood 13
Bologna 12
Hong Kong 12
Wayne 12
Amsterdam 11
Dallas 11
Redwood City 10
Reggio Emilia 10
Augusta 9
Brno 9
Houston 9
Dong Ket 8
Frankfurt am Main 8
Monmouth Junction 8
Ningbo 8
Rio Saliceto 8
Verona 8
Ardabil 7
Binche 7
Florence 7
Lanzhou 7
Neviano degli Arduini 7
Castello Molina di Fiemme 6
Fidenza 6
Fuzhou 6
Haikou 6
Leuven 6
Mestre 6
Ottawa 6
Paris 6
Salsomaggiore Terme 6
Taiyuan 6
Zhengzhou 6
Auburn Hills 5
Genoa 5
Busseto 4
Casalgrande 4
Chengdu 4
Fairfield 4
Ferrara 4
Kolkata 4
Mons 4
Montreal 4
Mumbai 4
Pavia 4
Pesaro 4
Albano Laziale 3
Albignasego 3
Borås 3
Budapest 3
Totale 5.078
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 137
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 133
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 131
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 125
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 120
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 117
Characterization of gefitinib uptake in NSCLC cell lines 116
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 114
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 108
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 108
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 104
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 99
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 98
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 98
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 97
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 97
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 96
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 95
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 95
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 93
Physico-chemical characterization and biological evaluation of two fibroin materials 93
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 93
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 93
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 92
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 90
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 89
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 89
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 88
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 88
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 86
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 86
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 86
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 85
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 84
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 83
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 83
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 82
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 81
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 79
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 79
Osteopontin is produced by human multiple myeloma cells 78
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 78
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 78
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 78
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 78
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 77
Multiple myeloma patient with unusual extramedullary involvement 77
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 76
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 75
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 73
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 73
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 73
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 73
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 73
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 71
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 70
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 69
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 69
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 69
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 69
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 69
Multiple myeloma patient with unusual extramedullary involvement 68
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 67
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 66
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 66
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 62
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 61
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 61
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 60
Optimizing EGFR inhibitor treatment in non small cell lung cancer 60
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 60
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 60
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 59
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 59
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 59
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 58
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 58
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 58
Synergistic activity of letrozole and sorafenib on breast cancer cells 57
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 57
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 57
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 55
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 53
RANKL is critically involved in the physiopathology of multiple myeloma 53
RANKL is critically involved in the physiopathology of multiple myeloma 52
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 52
Erlotinib potentiates Cetuximab-dependent cell citotoxicity in EGFR wild-type NSCLC cell lines 51
Interaction between occupational radon exposure and tobacco smoke: a systematic review 50
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 50
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 50
New therapeutic strategies for malignant pleural mesothelioma 50
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 48
Targeting FGFR1 pathway in squamous cell lung cancer 47
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 47
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 47
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 44
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 44
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 39
Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells 38
Human myeloma cells stimulate the receptor activator of NF-KB Ligad (RANKL) in T cells: Role of interleukin-7 35
Totale 7.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020642 0 0 0 0 0 131 154 47 102 101 53 54
2020/2021613 15 54 29 21 70 16 54 40 101 26 135 52
2021/2022574 36 15 52 41 20 25 88 50 31 22 40 154
2022/20232.246 211 239 153 152 198 248 45 143 700 17 101 39
2023/20241.015 35 75 35 47 82 186 86 85 44 55 105 180
2024/20251.227 137 138 187 198 282 285 0 0 0 0 0 0
Totale 7.738